Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05887609
Other study ID # 22-0384.cc
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 3, 2023
Est. completion date December 2027

Study information

Verified date May 2024
Source University of Colorado, Denver
Contact Samantha Hopp
Phone 3037240131
Email samantha.hopp@cuanschutz.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 53
Est. completion date December 2027
Est. primary completion date April 15, 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Provision to sign and date the consent form - Stated willingness to comply with all study procedures and be available for the duration of the study - Be a woman aged =18 years of age - Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 - Patients must have a confirmed diagnosis of high-grade serous or endometrioid EOC, primary peritoneal cancer, or fallopian tube cancer - Patients must have platinum-sensitive disease defined as radiographic progression greater than 6 months from last dose of most recent platinum therapy - Patients must have had documented complete or partial response, or stable disease, as defined by RECIST 1.1, from last line of platinum therapy - Patients must have available archival tissue block or slides to confirm FRalpha positivity - Patients' tumor must have FRalpha high or medium expression - Prior anticancer therapy: - Patients must have received at least one prior platinum-based chemotherapy regimen for platinum sensitive recurrent disease. - Most recent prior chemotherapy regimen must have consisted of at least 4 completed cycles and no more than 8 completed cycles - Most recent prior chemotherapy regimen must have been platinum based - Patients must have had testing for BRCA mutation (tumor or germline) and, if positive, must have received a prior PARP inhibitor as either treatment or maintenance therapy - Neoadjuvant +/- adjuvant therapies are considered 1 line of therapy - Maintenance therapy (eg, Bevacizumab, PARP inhibitors) will be considered part of preceding line of therapy (ie, not counted independently) - Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently) - Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance - Patients must have adequate hematologic, liver, and kidney function as defined as: - Absolute neutrophil count (ANC) = 1.5 x 109/L (1500/µL) - Platelet count = 100 x 109/L (100,000 µL) - Hemoglobin = 10.0 g/dL with no blood transfusion in the past 28 days - Serum creatinine = 1.5 x upper limit of normal (ULN) - Patients must have creatinine clearance estimated of =51 mL/min using the Cockcroft-Gault equation or based on a 24 hour urine test - Aspartate aminotransferase (AST)(Serum Glutamic Oxaloacetic Transaminase (SGOT)) and alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) = 2.5 x ULN unless liver metastases are present in which case they must be = 5x ULN - Serum bilirubin = 1.5 x ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin < 3.0 x ULN) - Serum albumin = 2 g/dL Exclusion Criteria: - Patients with clear cell, mucinous, sarcomatous, low grade/borderline, germ cell, or sex-cord stromal type ovarian tumor - Patients who have progressed through most recent chemotherapy regimen. Stable disease (SD) is permissible. - Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment - Patients with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions require ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision - Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML. - Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to: - Uncontrolled major seizure disorder - Unstable spinal cord compression - Any psychiatric disorder that prohibits obtaining informed consent. - Active hepatitis B or C infection (whether or not on active antiviral therapy) - Immunocompromised patients, e.g., patient who are known to be serologically positive for human immunodeficient virus(HIV) - Active cytomegalovirus infection - Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of MIRV - Patients with a history of multiple sclerosis (MS) or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome) - Patients with clinically significant cardiac disease including, but not limited to, any of the following - Myocardial infarction = 6 months prior to first dose - Uncontrolled ventricular arrhythmia, recent (within 3 months) - Superior vena cava syndrome - Unstable angina pectoris - Uncontrolled congestive heart failure (New York Heart Association > class II) - Uncontrolled = Grade 3 hypertension (per CTCAE) - Uncontrolled cardiac arrhythmias - Patients with a history of hemorrhagic or ischemic stroke within 6 months prior to enrollment - Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C) - Patients with a previous clinical diagnosis of noninfectious interstitial lung disease (ILD) or Extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan , including noninfectious pneumonitis - Persistent toxicities (>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia - Patients requiring use of folate-containing supplements (eg, folate deficiency) - Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks. - Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents. - Patients with prior hypersensitivity to monoclonal antibodies (mAb) - Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT). - Women who are pregnant or breastfeeding, and who do not agree to use a highly effective contraceptive method(s) while on study drug and for at least 3 months after the last dose of MIRV. Females of childbearing potential must have a negative serum pregnancy test within 72 hours of study entry. Refer to section 6.9.6 for details. - Patients who received prior treatment with MIRV or other FRa- targeting agents - Patients with duodenal stent or other GI disorder/defect that would interfere with absorption of oral medication - Includes patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication - Patients with known untreated or symptomatic central nervous system (CNS) metastases - Patients with a history of other malignancy within 3 years prior to enrollment - Note: patients with tumors with a negligible risk for metastasis or death (eg, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible - Prior known hypersensitivity reaction to study drugs and/or any of their excipients - Minor or major surgical procedure within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery. - Inability to comply with study and follow-up procedures - Patients deemed otherwise clinically unfit for clinical trial per investigators discretion

Study Design


Intervention

Drug:
Mirvetuximab Soravtansine
is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor a (FRa, the protein product of the folate receptor 1 [FOLR1] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).
Olaparib
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.

Locations

Country Name City State
United States University of Colorado Hospital Aurora Colorado

Sponsors (2)

Lead Sponsor Collaborator
University of Colorado, Denver ImmunoGen, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To measure progression free survival (PFS) with the use of MIRV combined with Olaparib in women with recurrent platinum sensitive ovarian, peritoneal, and fallopian tube cancer. PFS will be defined as the time from first dose of MIRV and Olaparib until investigator-assessed radiologic PD or death, whichever occurs first Through study completion, average of 12 months
Secondary To evaluate safety and tolerability of MIRV combined with Olaparib by Adverse Events as measured by CTCAE v 5.0 The team will use treatment-emergent adverse events (TEAEs) and laboratory test results, physical examination, or vital signs to determine AEs as described by CTCAE v5.0 Through study completion, average of 12 months
Secondary Determine Overall Response Rate Defined by confirmed best response of CR or PR as assessed by the investigator Through study completion, average of 12 months
Secondary Determine Duration of Response Defined as the time from initial investigator-assessed response (CR or PR) until progressive disease (PD) as assessed by the investigator Through study completion, average of 12 months
Secondary Determine Overall Survival Defined as the time from first dose of MIRV and Olaparib until death Up to 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03393884 - Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) Phase 1/Phase 2
Completed NCT04546373 - Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Active, not recruiting NCT05456685 - IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer Phase 2
Completed NCT01442051 - Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer N/A
Completed NCT02928549 - Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study
Active, not recruiting NCT03648489 - Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Phase 2
Not yet recruiting NCT04983550 - Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC Phase 2
Completed NCT02480374 - Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer Phase 1
Completed NCT01899599 - PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Phase 2
Completed NCT01610206 - A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer Phase 2
Completed NCT03480750 - Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer Phase 1/Phase 2
Completed NCT01031381 - Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer Phase 2
Completed NCT01219777 - Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian Phase 1
Completed NCT00959582 - Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) Phase 1
Suspended NCT00753480 - A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Phase 1
Completed NCT00768144 - Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma Phase 2
Completed NCT00801320 - Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer N/A
Completed NCT00702299 - Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer Phase 1
Recruiting NCT02349958 - Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Phase 2
Completed NCT00390234 - Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Phase 2